000078071 001__ 78071
000078071 005__ 20220120225831.0
000078071 0247_ $$2doi$$a10.1097/ADM.0000000000000375
000078071 0248_ $$2sideral$$a105270
000078071 037__ $$aART-2018-105270
000078071 041__ $$aeng
000078071 100__ $$aRodríguez-Cano, R.
000078071 245__ $$aThe interaction of depressive symptoms and hazardous drinking in relation to tobacco craving among treatment seeking depressed smokers: Sex differences
000078071 260__ $$c2018
000078071 5060_ $$aAccess copy available to the general public$$fUnrestricted
000078071 5203_ $$aObjectives: The present study sought to address whether there is sex effect in the interactive effect between depressive symptoms and hazardous drinking in the prediction of smoking craving after cognitive-behavioral smoking cessation treatment among those with at least mild depression.
Methods: Participants (n=114, mean age 42.0, SD=9.73, 64% women) were treatment-seeking smokers who attended 6 weekly 1-hour sessions involving psychological treatment for cessation. Participants reported depressive symptoms and alcohol use at baseline and reported craving at baseline and after treatment.
Results: Results indicated that there was a statistically significant 3-way interaction (depression by alcohol use by sex) for smoking craving (B=-0.30, standard error [SE]=0.14, P=0.042) and appetitive craving (B=-.21, SE=0.09, P=0.031), but not negative reinforcement craving. The form of the significant interactions indicted that higher levels of depressive symptoms and alcohol use were related to greater levels of craving at the end of treatment only among men.
Conclusions: The current findings provide novel empirical evidence suggesting that there is a clinically relevant interplay between depressive symptoms and alcohol use regarding general craving and appetitive craving among male treatment-seeking smokers. Although the present results should be replicated in larger samples, this type of research can inform the development of sex-specific interventions for smoking cessation.
000078071 536__ $$9info:eu-repo/grantAgreement/ES/MINECO/BES-2013-064101$$9info:eu-repo/grantAgreement/ES/MINECO/PSI2012-31196$$9info:eu-repo/grantAgreement/ES/MINECO/PSI2015-66755-R
000078071 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000078071 590__ $$a2.699$$b2018
000078071 591__ $$aSUBSTANCE ABUSE$$b11 / 19 = 0.579$$c2018$$dQ3$$eT2
000078071 592__ $$a1.192$$b2018
000078071 593__ $$aPsychiatry and Mental Health$$c2018$$dQ1
000078071 593__ $$aPharmacology (medical)$$c2018$$dQ1
000078071 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000078071 700__ $$aLópez-Durán, A.
000078071 700__ $$aPaulus, D.J.
000078071 700__ $$aMartínez-Vispo, C.
000078071 700__ $$0(orcid)0000-0002-9645-8109$$aFernández Del Rió, E.$$uUniversidad de Zaragoza
000078071 700__ $$aBeconã, E.
000078071 700__ $$aZvolensky, M.J.
000078071 7102_ $$14009$$2740$$aUniversidad de Zaragoza$$bDpto. Psicología y Sociología$$cÁrea Psicología Social
000078071 773__ $$g12, 2 (2018), 119-126$$pJournal of Addiction Medicine$$tJournal of Addiction Medicine$$x1932-0620
000078071 8564_ $$s221793$$uhttps://zaguan.unizar.es/record/78071/files/texto_completo.pdf$$yPostprint
000078071 8564_ $$s133596$$uhttps://zaguan.unizar.es/record/78071/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000078071 909CO $$ooai:zaguan.unizar.es:78071$$particulos$$pdriver
000078071 951__ $$a2022-01-20-22:54:32
000078071 980__ $$aARTICLE